Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

By S. Martino, J. Cauley, E. Barrett-Connor, T. Powles, J. Mershon, D. Disch, R. Secrest, Steve Cummings. Journal of the National Cancer Institute, 2004

655 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/1632c5f419346aba66d23dbf4f8f1fb92dbb6614

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Goldhirsch
2. Victor G. Vogel
3. A. Coates
4. R. Gelber
5. J. Costantino
6. C. Runowicz
7. B. Thürlimann
8. D. Wickerham

Citations in the corpus

• Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014, background): “indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
• Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010, positive): “Another SERM, raloxifene, has been shown to reduce the incidence of breast cancer in a series of clinical trials designed primarily to evaluate it for treatment and prevention of osteoporosis in postmenopausal women (7, 8).”
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006, background): “Previous studies have shown that raloxifenedoesnot increase the riskofuterinemalignancywhencomparedwithplacebo.(14,17,20) In the STAR trial, only 59 invasive uterine cancers were diagnosed in both study groups during more than 76 000 woman-years of follow-up.”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “Chemoprevention with raloxifene showed further reduction in invasive breast cancer incidence beyond 4 years of treatment in postmenopausal women with osteoporosis [4].”
• Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. (2010, methodology): “The Continuing Outcomes Relevant to Evista (CORE) and Multiple Outcomes of Raloxifene Evaluation (MORE) are placebo-controlled, randomized, double-blind trials examining the impact of raloxifene for preventing invasive breast cancer among postmenopausal women with osteoporosis (32).”
• Exemestane for breast-cancer prevention in postmenopausal women. (2011, neutral): “Back 106 77 21 2 306 (9) 119 80 23 222 (10) 0.”